Unveiling iTeos Therapeutics (NASDAQ: ITOS) Potential: Analysts Bullish on Belrestotug-Dostarlimab Combo for NSCLC Treatment
Piper Sandler reaffirms Overweight rating on iTeos Therapeutics (ITOS) with a $36.00 price target post ESMO data unveiling the efficacy of belrestotug and dostarlimab combo in treating PD-L1 high NSCLC. Analysts anticipate a surge in stock value following the promising results, including a 59% confirmed ORR compared to 28% for dostarlimab alone.
Despite safety signals, belrestotug's AE profile is comparable to Roche's tiragolumab. Recent interim data from the GALAXIES Lung-201 study also showed positive outcomes for the combination therapy. H.C. Wainwright maintains a Buy rating, while Wells Fargo initiates Overweight. iTeos reported a Q1 net loss slightly above projections and a $120 million stock sale.
InvestingPro Insights highlight iTeos's financial stability, market cap, and revenue growth challenges. The company does not pay dividends, but a 54.49% share price increase in the last six months reflects market optimism. Analysts revised earnings downwards, but the platform offers 9 additional insights for a deeper financial analysis. The fair value estimate is $18.57, indicating potential undervaluation compared to the $33.50 analyst target.
As iTeos progresses with belrestotug commercialization, stakeholders can leverage these financial insights amidst the biotechnology sector's volatility. This article, crafted with AI support and editor review, offers valuable information for investors seeking to capitalize on iTeos Therapeutics' potential in the market.